ViiV Healthcare announced the start of the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations), which aims to evaluate the best approaches to implementing an investigational, every-two-month, injectable HIV treatment regimen into clinical practice in Europe.
Inovio has announced the partial hold on its planned phase 2/3 trial of its Covid-19 vaccine candidate INO-4800 due to additional queries from the US Food and Drug Administration (FDA).
Arena Pharmaceuticals announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderately to severely active ulcerative colitis.
Millendo Therapeutics announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.
OncoImmune announced that its investigational immunomodulator SACCOVID (CD24Fc) has demonstrated significant therapeutic efficacy in the phase III SAC-COVID clinical trial.
Johnson & Johnson (J&J) has started a phase 3 trial for the JNJ-78436735 (Ad26.COV2.S) vaccine candidate developed by Janssen Pharmaceutical Companies for the prevention of Covid-19.
Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Chinese biopharmaceutical company Sinovac Biotech has begun phase III clinical trials for its inactivated Covid-19 vaccine candidate in Turkey.
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer.
Bristol Myers Squibb (BMS) said that the phase 3 CheckMate -649 trial showed that the Opdivo (nivolumab) plus chemotherapy delivered significant overall and progression-free survival benefits in first-line treatment of gastric and esophageal cancers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.